Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Wen Yan Zhong"'
Autor:
Luis A Diaz, Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardiere, Fernando Rivera, Elena Elez, Dung T Le, Takayuki Yoshino, Wen Yan Zhong, David Fogelman, Patricia Marinello, Thierry Andre
Publikováno v:
KEYNOTE-177 Investigators 2022, ' Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177) : final analysis of a randomised, open-label, phase 3 study ', The Lancet Oncology, vol. 23, no. 5, pp. 659-670 . https://doi.org/10.1016/S1470-2045(22)00197-8
Lancet Oncol
The Lancet Oncology, 23(5), 659-670. Lancet Publishing Group
Lancet Oncol
The Lancet Oncology, 23(5), 659-670. Lancet Publishing Group
Background: Pembrolizumab has shown improved progression-free survival versus chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. However, the treatment's effect on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02a04667b6513528277e21702f548f74
https://portal.findresearcher.sdu.dk/da/publications/141a15cb-1769-437d-8d1c-e6c02310d91d
https://portal.findresearcher.sdu.dk/da/publications/141a15cb-1769-437d-8d1c-e6c02310d91d
Autor:
Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen, Yuxian Bai, Wan Zamaniah Wan Ishak, Byoung Yong Shim, Young Lee Park, Dong‐Hoe Koo, Jianwei Lu, Jianming Xu, Hong Jae Chon, Li‐Yuan Bai, Shan Zeng, Ying Yuan, Yen‐Yang Chen, Kangsheng Gu, Wen Yan Zhong, Shu Kuang, Chie‐Schin Shih, Shu‐Kui Qin
Publikováno v:
Cancer. 128(5)
KEYNOTE-063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second-line therapy in Asian patients with advanced programmed death ligand 1 (PD-L1)-positive (combined positive score ≥1) gastric/gastroesophageal junction (GEJ) cancer.Thi
Autor:
Shukui Qin, Weijia Fang, ZhengGang Ren, Ou Shuangyan, Ho Yeong Lim, Feng Zhang, Hye Jin Choi, Jiandong Tong, Min Tao, Aibing Xu, Ashley Chi Kin Cheng, Chang-Hsien Lu, Chang-Fang Chiu, Mohamed Ibrahim A. Wahid, Shital Kamble, Josephine M. Norquist, Wen Yan Zhong, Chen Li, Zhendong Chen
Publikováno v:
Journal of Clinical Oncology. 40:4088-4088
4088 Background: In the randomized, double-blind, phase 3 KEYNOTE-394 trial (NCT03062358), pembro + BSC vs PBO + BSC as 2L therapy significantly reduced the risk of death by 21% (HR 0.79, 95% CI 0.63-0.99, P= 0.0180), prolonged PFS (HR 0.74, 95% CI 0
Autor:
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek-Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xing Ye, Jieer Ying, Jianfeng Li, Wen Yan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Publikováno v:
Journal of Clinical Oncology. 40:383-383
383 Background: The anti–PD-1 antibody pembro showed efficacy and manageable safety in the global phase 2 KEYNOTE-224 and phase 3 KEYNOTE-240 studies of patients (pts) with previously treated advanced HCC, a population of high unmet need. KEYNOTE-3
Autor:
Christelle De La Fouchardiere, Julia Alcaide, Lars Henrik Jensen, Elena Elez, Tae Won Kim, Benny Vittrup Jensen, Cornelis J. A. Punt, Kai-Keen Shiu, Rocio Garcia-Carbonero, Denis Smith, Johanna C. Bendell, Thierry André, Luis A. Diaz, Dung T. Le, Patricia Marinello, Fernando Rivera, Takayuki Yoshino, Peter Gibbs, David R. Fogelman, Wen Yan Zhong
Publikováno v:
Andre, T, Shiu, K-K, Kim, T W, Jensen, B V, Jensen, L H, Punt, C J A, Smith, D M, Garcia-Carbonero, R, Alcaide, J, Gibbs, P, De la Fouchardiere, C, Rivera, F, Elez, E, Bendell, J C, Le, D T, Yoshino, T, Zhong, W Y, Fogelman, D R, Marinello, P & Diaz, L A 2021, ' Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). ', Journal of Clinical Oncology, vol. 39, no. Suppl. 15 . https://doi.org/10.1200/JCO.2021.39.15suppl.3500
3500 Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with M